Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Welcome back River! NEWS is coming soon! I think! LOL!
And as good a guy as Jack is I sense a little pessimism and we cannot have that here at least not alone! LOL! He is wrong though!
I know Jack is probably sitting there thinking, It Just Can't Be! But it's true something has indeed changed! We Are Getting Closer! LOL!
To what I am not sure! But I am sure we must be getting closer! So he is indeed wrong! Sorry Jack! Much respect! But I have to call you out on this one! LOL! We can't know everything! But I am sure they are a number of us give our best damn try! LOL!
Go Proelite!
I hear you! But you know me I stick by thought something is going to happen and here's my guess at this point by Wednesday of the coming week! Or maybe some point shortly afterwords! I have to give myself something of an out! LOL!
To be honest as much many including myself wanted to believe something may happen faster in actual reality Stratus did elude to a notice of one or more shows in 2010, now whether that means the actual show(s) would or will happen before year end I do not believe that was actually indicated and it would be nice but I think at this point solid planning and execution are more important and we have to think and hope they are going to make it worth the wait!
Go Proelite!
I can see your hopes remain high! LOL! I think 50 years should be more than enough! I'm much more optimistic than you are are! LOL!
LMAO! Come on give them some slack! It will be well before 2074!
Josh Thomson Feels WEC/UFC Merger Was Nice Way Of Saying WEC Failed
Josh "The Punk" Thomson, who is a a former Strikeforce lightweight champion, talked this week about the WEC/UFC merger and broke down why he feels the WEC was a less than superior product to that of his home, Strikeforce:
"They made it sound so great that a company went under. The simple fact of the matter was that the WEC failed and they put it with the UFC to carry it."
"To compare WEC lightweights to Strikeforce and the UFC is not fair because if they were that good, they would have been fighting for the UFC. I think the world of (Jamie) Varner, but I beat Hermes (Franca) and Hermes beat Varner. Varner was the WEC champ for awhile. So, where does that leave us?"
http://www.mmanews.com/news/88899
No convincing needed here as I agree! I think Stratus has acted very slowly which has and will come at a price for them and Pro and I think that is reflected in their Stock Price and Pro's for that matter as the price should be much higher with Chuck Champion's moves with the company alone! For the most part elimination of debt and ongoing revenue generation but that cannot continue unchecked and with no plan to increase revenues and Brand awareness as those values will continue to decline if held too long and the existing Contracts end.
They should be working on building the Brand and I think on or before a show really makes no difference as long as there is a plan and it's worth wait, well planned and successful in both the plan delivery and execution!
I think they would be judged fairly and appropriately as well as personally think they have alot to work with as Pro has been before and can and will be a major Brand in MMA with or without them!
That being said I still want to believe that Stratus's intentions are good and the Plan is still unfolding with next steps close at hand but the count down is on and in my view yes they must get things underway as I believe like many their investment is depreciating! Let's go Stratus!
Go Proelite!
"ProElite, a globally recognized brand, is a great addition to our portfolio of companies and live entertainment events and provides an experienced management team with demonstrated success in operating MMA events and generating broadcast revenues," stated Paul Feller, President of Stratus. "By combining ProElite with sufficient capital and Stratus' strengths in event production and sponsorship sales, we intend to re-establish ProElite as a leading international MMA company."
Go Proelite! Let's make this happen!
OXiGENE, Inc. (OXGN) Bouncing Back From 52-week Low
November 10th, 2010 at 1:21 pm Posted by George Harrison
Shares of OXiGENE, Inc. (NASDAQ:OXGN) are rising this morning and now up 18.50% to $0.261. Today’s rise came after the stock made a new 52-week low of $0.21 on Monday. More than, 4.50 million shares have traded hands, compared to its daily average volume of 1.55 million shares.
The stock had been not moving much over the past couple of months and was trading with a range of $0.30-$0.25.
Nov. 4, the company announced its third quarter results.
The company had reported consolidated net loss of $13.5 million, compared to a year ago loss of $6.9 million.
The net loss applicable to common stock was $0.17 per share for the three-month period ended September 30, 2010, compared to $0.29 per share for the same three-month period of 2009.
Shares of PCBC have slumped over 76% so far this year. The stock is trading below its 50-Day Moving Average and 200-Day Moving Average of $0.26 and $0.46 respectively.
http://collegestock.com/blog/770-oxigene-inc-oxgn-bouncing-back-from-52-week-low/
Agreed as well! We all have to hope Stratus has this under control and while everybody else is out driving around in Cars trying to figured out how to cross an Ocean while Stratus/Proelite have been waiting are now done and getting ready to hit the Launch Button!
9..8..7..6..5..4..3..2...1...Let's Go Proelite!
GO PROELITE!
0.0003 or -25.00% Current price! This is crazy the Float will be over 1 Billion Shares if it's not already with over 930 Million Shares in the Float as of Oct 21 / 2010! Come on Mundus make something happen other than telling us about some presentation or describing potential uses other than killing bugs! When are they going to actually sell something other than Shares and continue to driving down the price! I guess they have another Billion Shares to go! They need at new Plan or at least a Plan!
Highest Bid at .27 with one one at that price and the rest .26 and lower, Last sale at .32 and many sales today at .30 or under! Not looking good the company needs to get something underway fast!
Some how the site the image was associated with changed the image! I have now changed the image set and it should look proper now!
With you all the way! Pro was moving along in my view quite well making small but notable deals under Chuck Champion and things now seemed to be slowed down to crawl! A Very Slow Crawl if ever there was such a thing but I have to Think/Hope Status have some up their sleeve and are just being very careful and for that matter sure before releasing anything that may or may not be complete! I have to think they have a Plan and it's just been slow coming maybe even a little or alot slower than they or any of us thought! Call me a fool but I think we will see something soon!
"
Name Stratus Media
Location Santa Barbara
Web http://www.prosportsinc.com/
Bio We are a media company that is currently working on many projects in the entertainment world and auto world."
http://twitter.com/stratusmedia
Go PELE
This is awesome! This project looks fantastic with another big dog and huge legendary player in the comic industry!
"The Archie Comics line of comic books is one of the most successful, longest running brands in the history of the comic industry. Archie Comics have sold 1.5 billion comics and are published in a dozen different foreign languages and distributed all over the world. Archie Comics has spawned characters whose popularity has spilled over into other media and who have become part of popular culture. SABRINA THE TEENAGE WITCH and JOSIE AND THE PUSSYCATS are just some of the many legendary franchises that are part of the Archie Comics Library."
http://www.archiecomics.com/aboutus/company_biography/index.html
Go POW!
Updated Share Counts in the IBox/Intro Message
Period as of Oct 21, 2010
Number of Shares Authorized 2,000,000,000
Number of Shares Outstanding 1,151,256,855
Float 930,018,873
Highest and only Buy Bid Price .30! all the rest at .26 and lower! Confused by this one! Let's go Stratus!
8 Cancer Innovators to Watch - Includes OXiGENE Inc
by: Douglas Cress November 09, 2010
By Vanderson
Cancer drug sales are slowing down in the U.S., Reuters reported Monday. According to pharmaceutical research firm IMS Health, U.S. sales of oncology drugs increased only 3.5 percent in the first nine months of 2010, compared to sales growth of 23 percent in 2006, 14 percent in 2007, and 9 percent in 2008 and 2009. The slowdown in sales growth is primarily being caused by price increases as well as the entry of new generics as older, established drugs lose patent protection. The article also noted that many recent drugs are simply variations of existing drugs that wind up jostling for space in an already crowded market.
The article notes that the oncology field will largely be driven by innovation. Those seeking the cancer innovators of tomorrow might take a look at the following companies:
ImmunoCellular Therapeutics‘ (IMUC.OB) cancer vaccine has drawn comparisons to Dendreon’s (DNDN) Provenge. ImmunoCellular is currently advancing a dendritic cell-based vaccine to treat glioblastoma multiforme, the most common form of brain cancer.
Antigenics’ (AGEN) lead product, Oncophage, is a therapeutic cancer vaccine that is formulated to target only cancerous cells. The company is currently recruiting patients for Phase I and II studies of its cancer vaccine for brain and central nervous system tumors. Antigenics was recently awarded $424,720 in grants under the IRS’ Qualifying Therapeutic Discovery Project (QTDP) program for promising therapeutic candidates.
Although Mannkind Corp.’s (MNKD) insulin inhaler (currently in clinical development) has gained the most media attention, the company is also developing a therapeutic cancer vaccine. Last month, the company initiated a Phase II study of its immunotherapy vaccine in patients with advanced melanoma.
Both Curis (CRIS) and Ariad Pharmaceuticals (ARIA) are developing cancer treatments which utilize cell signaling pathways that are linked to cancer.
Coronado Biosciences and Cleveland BioLabs (CBLI) are both developing drugs that target the process of apoptosis, or programmed cell death. Cleveland BioLabs recently dosed the first patient in a multicenter Phase Ib trial of curaxin in patients with liver tumors. The company was also awarded a $244,479 grant under the QTDP program.
Nanospectra Biosciences’ technology turns light into heat for the focused, thermal destruction of solid tumors. On the opposite end of the temperature scale, NuVue Therapeutics utilizes cryotherapy for the site-specific targeting of soft tissue tumors.
OxiGene (OXGN) is targeting ovarian cancer using a new type of therapy known as “vascular disrupting agents,” which works by collapsing the blood vessels inside of the tumor and “starving” it from within.
Threshold Pharmaceuticals (THLD) is developing a tumor-targeting therapy for pancreatic cancer and other solid tumors. The company’s therapeutic platform is based on the concept of “tumor hypoxia,” or low oxygen concentration in the tumor. Threshold’s lead drug candidate, TH-302, is formulated to be activated within hypoxic cells, killing them and those nearby. The drug has demonstrated significant anti-tumor activity in preclinical studies.
http://seekingalpha.com/article/235637-8-cancer-innovators-to-watch?source=yahoo
8 Cancer Innovators to Watch - Includes OXiGENE Inc
by: Douglas Cress November 09, 2010
By Vanderson
Cancer drug sales are slowing down in the U.S., Reuters reported Monday. According to pharmaceutical research firm IMS Health, U.S. sales of oncology drugs increased only 3.5 percent in the first nine months of 2010, compared to sales growth of 23 percent in 2006, 14 percent in 2007, and 9 percent in 2008 and 2009. The slowdown in sales growth is primarily being caused by price increases as well as the entry of new generics as older, established drugs lose patent protection. The article also noted that many recent drugs are simply variations of existing drugs that wind up jostling for space in an already crowded market.
The article notes that the oncology field will largely be driven by innovation. Those seeking the cancer innovators of tomorrow might take a look at the following companies:
ImmunoCellular Therapeutics‘ (IMUC.OB) cancer vaccine has drawn comparisons to Dendreon’s (DNDN) Provenge. ImmunoCellular is currently advancing a dendritic cell-based vaccine to treat glioblastoma multiforme, the most common form of brain cancer.
Antigenics’ (AGEN) lead product, Oncophage, is a therapeutic cancer vaccine that is formulated to target only cancerous cells. The company is currently recruiting patients for Phase I and II studies of its cancer vaccine for brain and central nervous system tumors. Antigenics was recently awarded $424,720 in grants under the IRS’ Qualifying Therapeutic Discovery Project (QTDP) program for promising therapeutic candidates.
Although Mannkind Corp.’s (MNKD) insulin inhaler (currently in clinical development) has gained the most media attention, the company is also developing a therapeutic cancer vaccine. Last month, the company initiated a Phase II study of its immunotherapy vaccine in patients with advanced melanoma.
Both Curis (CRIS) and Ariad Pharmaceuticals (ARIA) are developing cancer treatments which utilize cell signaling pathways that are linked to cancer.
Coronado Biosciences and Cleveland BioLabs (CBLI) are both developing drugs that target the process of apoptosis, or programmed cell death. Cleveland BioLabs recently dosed the first patient in a multicenter Phase Ib trial of curaxin in patients with liver tumors. The company was also awarded a $244,479 grant under the QTDP program.
Nanospectra Biosciences’ technology turns light into heat for the focused, thermal destruction of solid tumors. On the opposite end of the temperature scale, NuVue Therapeutics utilizes cryotherapy for the site-specific targeting of soft tissue tumors.
OxiGene (OXGN) is targeting ovarian cancer using a new type of therapy known as “vascular disrupting agents,” which works by collapsing the blood vessels inside of the tumor and “starving” it from within.
Threshold Pharmaceuticals (THLD) is developing a tumor-targeting therapy for pancreatic cancer and other solid tumors. The company’s therapeutic platform is based on the concept of “tumor hypoxia,” or low oxygen concentration in the tumor. Threshold’s lead drug candidate, TH-302, is formulated to be activated within hypoxic cells, killing them and those nearby. The drug has demonstrated significant anti-tumor activity in preclinical studies.
http://seekingalpha.com/article/235637-8-cancer-innovators-to-watch?source=yahoo
Brock the Bully: Former Champion Brock Lesnar Looks for Easier Prey
by JonathanSnowden on Nov 3, 2010 12:00 PM EDT in UFC Editorial
They say you see the true heart of a champion only after they've been knocked down. After all, how can you gauge how well a man responds to adversity if he's never even been tested? Well, Brock Lesnar has been tested in the Octagon - and found wanting.
Against Shane Carwin he ran across the cage to avoid thunderous blows. Against Cain Velasquez he wasn't even allowed that much dignity, pirouetting and cartwheeling around the Octagon like he was part of a drunken dance recital. You'd expect a true champion and a title contender to be clamoring to get back in the cage with his conqueror. To want to prove he is as good as the hype, to reestablish his place in the pecking order. But there's a question about who Brock Lesnar is at his core.
Simply put, Brock is a bully. When backed into a corner his instinct isn't to take the hard path. It's to find prey he thinks he can conquer - and attack. Bryan Alvarez, editor of the Wrestling Observer's sister newsletter Figure Four Weekly, says Brock isn't looking to rematch Carwin or get a return bout with Velasquez. Instead, Lesnar reportedly has set his sights on Roy Nelson.
Now there's nothing wrong with Roy Nelson. He's a talented fighter, a mid-level heavyweight contender who is most famous for hiding a 205 pound potential champion inside a 265 pound rolly polly package. But isn't it a little odd for a former champion, the UFC's flagship fighter, to be challenging a guy who's best career win was against prospect Brendan Schaub? Nelson isn't a top-shelf contender. He's a guy who has fallen short time and again against the top level competition he's faced, including a recent beating incurred at the hands of heavyweight contender Junior dos Santos.
Contrast Lesnar's approach to the recently vanquished heavyweight kingpin Fedor Emelianenko. Fedor didn't respond to his loss to Fabricio Werdum by challenging Jeff Monson. He asked for a rematch with the man who made him tap:
"Certainly I would like to have a rematch with Fabricio. If he agrees, I would love to do that. The one who doesn't fall doesn't stand up. It happens that I was made kind of an idol. Everybody loses. That happens. I'm a normal human being, as are all of us. If it is God's will, the next fight I'll win."
So why is Lesnar challenging a fighter who isn't in the title hunt? Because he thinks it's easier. He thinks he can roll right over the fat kid - and he's probably right. But even asking for this fight shows plenty about Lesnar and where he is mentally. This isn't the confident move of a fighter on his way back up the ladder. This is the path of the bully, the more favorable route, and the mindset of a fighter still a little shell shocked after consecutive shellackings.
http://www.bloodyelbow.com/2010/11/3/1791108/brock-the-bully-former-champion-brock-lesnar-looks-for-easier-prey
IBox has been updated! It is a very exciting time for POW! and us for that matter! What a huge year this going to be with so many Projects already being released and so many more in the coming couple of months much less in various stages of release and development for next year and many years beyond!
Go POW!
Revenue up 21% sequentially over Q2 201 - Cambridge Heart Reports Results for the Three and Nine Months Ended September 30, 2010
Revenue up 21% sequentially over Q2 2010
TEWKSBURY, Mass.--(BUSINESS WIRE)--Cambridge Heart, Inc. (OTCBB: CAMH), today reported results for the three and nine months ended September 30, 2010. Full financial statements and corresponding commentary can be found in the Company’s Form 10-Q, which is expected to be filed with the Securities and Exchange Commission on November 15, 2010. The following financial and strategic milestones highlight the third quarter:
“We believe that the outstanding brand recognition of Cardiac Science’s product lines, when combined with a larger global presence and greater financial strength is a positive development for our partnership.”
* Revenue – Sales for the third quarter were $793,000, an increase of 21% compared to $654,000 in the second quarter of 2010. The Company believes the recent reimbursement change in July 2010 contributed to the increase in revenue.
* Distribution Update – The MTWA Module was launched on September 21, 2010 through the Company’s distribution partner, Cardiac Science Corporation, Inc., which was in line with the launch plans. From the launch date through September 30th, the Company shipped an initial order of 10 MTWA modules to Cardiac Science.
* Clinical Update – The Company began enrolling patients in a second clinical site for its’ MTWA-CAD study, (the study is designed to determine if the Company’s MTWA testing can enhance current diagnostic methods for detecting ischemia in patients with underlying coronary artery disease). The MTWA-CAD trial is a pilot study expected to enroll up to 200 patients. The Company estimates that the enrollments will be completed by mid-2011.
Commenting on the results of the quarter and recent events, Cambridge Heart CEO Ali Haghighi-Mood said, “In the third quarter, the commercial launch of the MTWA Module marked the key milestone of the new strategy we announced last year. We are very pleased with the initial level of activity in promoting and marketing the MTWA Module, and the cooperation between our respective sales and marketing teams. While it is too early to comment on the ultimate rate of adoption, we are encouraged by the activity level seen to date and the growth of the sales pipeline”. In regards to the recently announced tender offer by Opto Circuits (India) Ltd. to acquire Cardiac Science Corporation, Haghighi-Mood added, “We believe that the outstanding brand recognition of Cardiac Science’s product lines, when combined with a larger global presence and greater financial strength is a positive development for our partnership.”
Financial Results for the Three and Nine Months ended September 30, 2010
Total revenue for the third quarter ended September 30, 2010 was $793,000, compared to total revenue of $798,000 reported during the same period of 2009. Sales continue to be adversely impacted by ongoing weakness in the sales of medical equipment in general, our limited scope of distribution, and the uncertainty around certain reductions in reimbursement. Cost of sales for the third quarter of 2010 was $535,000, compared to $456,000 in the same period in 2009. Gross profit, as a percent of revenue, for the three months ended September 30, 2009 and 2010, was 43% and 33%, respectively. The decrease in gross profit compared to 2009 is due to start-up manufacturing costs in connection with the MTWA Module and more than average number of treadmills included in orders of the HearTwave II System. The reserve against inventory the Company established, which was based on the uncertainty that the Company will realize the full value of the existing inventory over the next 12 months, was unchanged. The inventory was built up in order to satisfy our contractual obligations under the former co-marketing agreement with St. Jude Medical. Operating expenses for the third quarter of 2010 were $1,378,000, a decrease of $645,000, or 32%, compared to $2,023,000 in the third quarter of 2009. The decrease in operating expense is driven by lower selling, general and administrative expenses related to consultative and advisory activities, lower non-cash compensation due to the full vesting of certain previously issued stock option and restricted stock awards, and some reduction in headcount in 2010. The operating loss for the third quarter of 2010 was $1,121,000, compared to an operating loss of $1,681,000 for the same period last year. Included in the operating loss for the third quarter of 2010 was $195,000 of non-cash stock-based compensation expense. The net loss for the quarter was $1,123,000 or $0.02 per share, compared to a net loss of $1,681,000, or $0.03 per share, in the comparable 2009 period. For the nine months ended September 30, 2010, total revenue was $2,105,000, a decrease of $322,000, or 13%, compared to total revenue of $2,427,000 for the same period in 2009. Operating expenses for the nine-month period in 2010 were $4,567,000 compared to $6,641,000 in 2009. The operating loss for the nine month period ended September 30, 2010 of $3,938,000, which included a $124,000 inventory reserve charge, decreased $1,687,000 compared to an operating loss of $5,625,000, for the same period in the prior year. The operating loss for the nine-month period ended September 30, 2010 included $792,000 in non-cash stock based compensation expense compared to $1,507,000 for the nine-month period ended September 30, 2009. The net loss for the nine-month period ended September 30, 2010 was $3,946,000, or $0.06 per share, compared to a net loss of $5,616,000, or $0.09 per share, during 2009. Cost of sales for the nine months ended September 30, 2010 was $1,476,000 (which includes a $124,000 charge to reserve for potentially excess inventory) compared to $1,411,000 in the same period in 2009. Gross margin as a percent of revenue for the nine months ended September 30, 2010 was 30% compared to 42% in 2009. This decrease in gross margin is primarily attributable to the $124,000 inventory reserve provision, recorded in the first six months ended June 30, 2010, in connection with inventory built up to satisfy our contractual obligations under the arrangement with St. Jude Medical, coupled with start-up manufacturing costs in connection with the MTWA Module and above average number of treadmills at no charge were included in orders of the HearTwave II System in the third quarter. The Company ended the third quarter with unrestricted cash and cash equivalents of $1,516,000. The cash used by operations was $3,072,000 for the nine months ended September 30, 2010. The Company believes that the existing resources and currently projected financial results, which include sales of the MTWA Module and Micro-V Alternans Sensors to Cardiac Science, are sufficient to fund operations through December 31, 2010. The projections do not include the potential additional proceeds of up to $752,000, $0.107 per share, from the exercise of the previously unexercised Short-Term Warrants that were issued in connection with the Series D Private Placement, which expire on December 23, 2010. In the event the remaining outstanding Short-Term Warrants are exercised, the Company believes it would have sufficient resources to fund its operations through March 31, 2011. The Company currently has a total of 102.7 million shares of common stock and common stock equivalents issued and outstanding, including the effect of converting the Series C-1 preferred stock and the Series D preferred stock into shares of common stock. In addition, there are options and warrants outstanding to purchase 16.9 million shares of common stock, bringing the fully diluted share count to 119.7 million shares of common stock.
http://www.businesswire.com/news/home/20101103005490/en/Cambridge-Heart-Reports-Results-Months-Ended-September
Joey Lawrence-Wesley Snipes action film 'Havana Heat' even crazier/better than we thought!
by Mandi Bierly
Lawrence-SnipesImage Credit: Bob Charlotte/PR Photos; Mark Dye/PR PhotosIf, like us, you read the Variety headline “Snipes, Lawrence join ‘Havana Heat’” and needed to know more about the indie action film costarring Wesley Snipes and Joey Lawrence shooting this November, prepare to be very happy. Producer James Ordonez, president of Tayrona Entertainment Group, just gave EW some serious details about the movie and its efforts to be the next Expendables (yes, offers are out to Chuck Norris and Jean-Claude Van Damme!).
• We begin with the plot: “Havana is a mysterious, sensuous city with gorgeous architecture, white Caribbean beaches, hot, pulsating music, vintage American automobiles and some of the most beautiful women in the world. CID Special Agent Sean Franklin [Lawrence] and his partner, gung-ho rookie, NCIS Special Agent Brianna Evans [Fighting's Zulay Henao] are assigned undercover in Havana after another agent is murdered. At the same time, a heavyweight fight between American Ruben Palace and Cuba’s Kid Carlos becomes an international incident when a girl Ruben meets in a salsa club is found dead. Sean and Brenda team up with National Revolutionary Police Force Detective Jose Aguillerra to uncover the mystery behind both crimes.”
• Where does Snipes come in? “Snipes plays Major Evans, Sean Franklin’s boss and father of his assigned rookie partner…. Major Evans coordinates all the infiltration operation in Cuba and will engage once he finds out his best man and daughter are in danger,” Ordonez says. What made producers think to pair Lawrence and Snipes? “As a coincidence with The Expendables, Havana Heat was put together as a retro ’80s action all-star movie. We were looking for a very big teen 1990s idol who still is young and fresh to play the lead action role, and Joey Lawrence was the perfect candidate,” he says. “Wesley Snipes is one of the most recognized action stars of all times… so it was perfect to put them together.”
• This all-star movie may include Jean-Claude Van Damme. “Raul Julia-Levy, son of late Raul Julia is also part of the cast, and he’s personally convincing Jean-Claude Van Damme to join the cast as well in order to have a major fighting scene that will reprise the final fight between Van Damme and Raul Julia in the 1994 action flick Street Fighter, which was Raul Julia’s final movie,” Ordonez says. Julia-Levy plays a Cuban driver with a secret, and Van Damme is being courted for the role of Mikhail Guzman, a hardcore criminal and human trafficker. Producers are also in talks with Chuck Norris (to play Commander Winston, Snipes’ superior) and The Terminator‘s Michael Biehn (to play Warrant Office Pelski, who’s been training Henao at GITMO). Whether or not those three deals get signed, the confirmed supporting players include: The Expendables’ Randy Couture as Bruno Bresler, the manager of the American boxer (who’ll be played by UFC fighter Heath Herring); La Femme Nikita‘s Peta Wilson as Captain Camille Davenport, who’s been helping Lawrence’s character, on bereavement leave when he gets the call to Cuba, work through his troubled past; American Ninja‘s Michael Dudikoff as Lawrence’s ex-partner who gets shot in Cuba; Zorro: La Telenovela‘s Lorena Rincon as the assassin; and Bollywood star Nicholas Brown (Kites) as a criminal involved in extortion and gambling.
http://popwatch.ew.com/2010/08/19/joey-lawrence-wesley-snipes-havana-heat/
As Tom has show http://proelite.com/ or use http://www.proelite.com/ works as well! So Yes they have a Web Site and this has been all in preparation of the big Launch under the NEW Company!
Go Proelite
http://www.proelite.com/
Volume: 12,304,831 Spent most of the day at 0.0004! or -20% for those who bought at 0.0005! Somebody who bought a hand full shares kicked it up to a big 0.0005 for the end of day!
LOL! Yep! It's one he is better suited for given past and current career aspirations as an entertainer! And the UFC BIG announcement another big surprise or announcement for that matter, not at all! Everybody seen and heard it was coming from a mile away! Another Promotion absorbed into UFC/killed off not that it's anywhere near the same level or in the same class but very much A LA Pride Fighting Championships!
Not attempting to be hard on this point but it's very hard to believe there is not severe dilution going on with this company with or without a formal press release which we all know the company will never do as it's the one doing it!
It is not unusual for us to see 20+ million shares sold per day and many many many more on any given day and the company did move the number of Shares Authorized up to 2,000,000,000 as reflected in the Intro/Ibox Information. Since Jan of this year alone we have watched the Share price fall from 0.057 to today's price of 0.0005 The dilution has and continues to kill the stock price!
I and I believe all are here and have invested because they atleast some point have believed in the company and unfortunately have all continued to lose while the company figures it's way out while using Share Sales to pay the bills.
If anyone has something that shows the contrary please present it as the share volumes are public fact and speak for themselves with no notable revenues in sometime as the financial reports continue to state as public record as well.
This company does need a new Plan and needs to quit diluting it's stock and driving down the share price!
Brock Lesnar Paid TWICE as Much as UFC Champ Cain Velasquez
Written by Tom Ngo
October 26th, 2010
UFC Brock Lesnar Cain Velasquez 121
Despite leaving The OC with the heavyweight title in tow, newly crowned king Cain Velasquez pocketed only $200,000 for slapping Brock Lesnar silly at UFC 121 inside the Honda Center in Anaheim.
Former WWE superstar Brock Lesnar earned a $400,000 salary for his four minutes and 12 seconds of work. That works out to approximately $1,587/second.
The California State Athletic Commission released the official paydays for all the athletes that competed in this past Saturday’s pay-per-view extravaganza. The star-studded roster cost the world’s premier MMA organization a disclosed $1.513 million in total.
UFC president Dana White reported at the post-fight press conference that the company garnered a $2.15 million at the gate. Please don’t think for a second the Octagon just barely broke even, with possible record-setting PPV numbers expected for the highly hyped event.
Please keep in mind, the numbers that get reported to the athletic commissions are only of what’s required. These figures do not include deductions for items such as insurance, licenses and taxes.
Additionally, they do not contain money paid by sponsors or any bonuses from the UFC. These royalties can include pay-per-view commissions, Fight Night bonuses, secret somethin’ somethin’ handshakes, etc., which can oftentimes represent a substantial portion of a fighter’s total income
http://www.5thround.com/57158/brock-lesnar-paid-twice-as-much-as-ufc-champ-cain-velasquez/
Brock did not look interested in taking him on! But the Undertaker is one big dude so I can't blame him there! Brock is big even if he did get his butt kicked by Cain! But the Undertaker is huge and I think in a real fight he would easily bust Brock up.